Suppr超能文献

政府法规与药物使用。

Government regulations and the use of drugs.

作者信息

Hafkenschiel J H

出版信息

Calif Med. 1967 Aug;107(2):159-63.

Abstract

I have tried to trace the new drug development pattern from 1766, when Withering obtained his medical degree, to the present. The role of governmental authority as defined by the 1962 Kefauver-Harris amendments to the 1906 law and the subsequently issued regulations has been summarized. Four phases of testing in man have been detailed. Something of the scientific or research capability of the pharmaceutical industry has been presented. It is concluded that in the period of over two hundred years of medical education in the United States, the university hospital has become more and more the focus of medical research, teaching and practice in the community. The safety and effectiveness in the use of drugs in the future will depend upon the liaison and rapport of the industry physicians, government officials and the university hospital teacher-clinical investigators (phase 1 and 2) in designing the most critical studies of the safety and effectiveness of new drugs. Whether the medical profession as we know it will participate more in the future than has been possible since 1962 in mass clinical trial (phase 3) before new drug approval by governmental authority remains to be seen. The final approbation or disapproval of a drug after NDA approval (phase 4) will continue to be in the hands of the participating physician as long as he can establish scientifically that the drug is the best possible agent for him to use in healing the sick and comforting the dying.

摘要

我试图追溯自1766年威瑟林获得医学学位以来的新药研发模式,直至当下。总结了1962年对1906年法律的凯弗维尔-哈里斯修正案及随后发布的法规所定义的政府当局的作用。详细阐述了人体试验的四个阶段。介绍了制药行业的一些科学或研究能力。得出的结论是,在美国两百多年的医学教育历程中,大学医院越来越成为社区医学研究、教学和实践的焦点。未来药物使用的安全性和有效性将取决于制药行业的医生、政府官员以及大学医院的教师临床研究人员(第1和第2阶段)在设计新药安全性和有效性的最关键研究时的联络与融洽合作。自1962年以来,在政府当局批准新药之前,我们所知的医学专业在大规模临床试验(第3阶段)中未来是否会比以往更多地参与其中,仍有待观察。只要参与的医生能够科学地证明该药物是他用于治疗病人和安慰垂死者的最佳药物,那么在新药申请批准后(第4阶段)对药物的最终批准或否决将继续掌握在该医生手中。

相似文献

2
[The origin of informed consent].[知情同意的起源]
Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27.
9
Lessons learned from independent central review.独立中央审查的经验教训。
Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

本文引用的文献

1
USE AND ABUSE OF DRUGS.
Br Med J. 1965 Aug 21;2(5459):437-41. doi: 10.1136/bmj.2.5459.437.
2
THE PHYSICIAN AND THE FOOD AND DRUG ADMINISTRATION.医生与食品药品监督管理局
JAMA. 1964 Dec 7;190:907-9. doi: 10.1001/jama.1964.03070230043011.
5
New drugs: the AMA and the FDA.
Ann Allergy. 1966 Jul;24(7):333-6.
6
Perspectives in toxicology.毒理学视角
Toxicol Appl Pharmacol. 1966 Jan;8(1):1-5. doi: 10.1016/0041-008x(66)90093-7.
8
The gap between pharmacology and therapeutics.
J New Drugs. 1966 Mar-Apr;6(2):69-76.
9
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验